Key Highlights

  • Revenue was USD 328 thousand against an estimate of USD 96 thousand.
  • Loss per share was USD 0.02, matching an estimate of a USD 0.02 loss.
  • Gross Margin decreased to 19% from 52% a year earlier.
  • Cash was approximately USD 377 thousand at September 30.

IGC Pharma (NYSE American:IGC) reported third quarter 2026 Revenue of USD 328 thousand, against an estimate of USD 96 thousand. The loss per share was USD 0.02, matching the estimate of a USD 0.02 loss. The company reported the figures in thousands in its quarterly filing for the period ended September 30, 2026.

Cost of revenue was approximately USD 267 thousand, compared with approximately USD 92 thousand in the prior-year quarter, and gross margin decreased to 19% from 52%.

Operating Expenses and Net Loss

Selling, general and administrative expenses were USD 979 thousand, compared with USD 1,410 thousand a year earlier. Research and Development expenses were USD 1,013 thousand, compared with USD 1,588 thousand. The operating loss was USD 1,931 thousand, against USD 2,899 thousand.

Other expense, net, was approximately USD 115 thousand, compared with other income of approximately USD 1.1 million in the third quarter of 2025. The loss before income taxes was USD 2,046 thousand, against USD 1,821 thousand, and net loss per share was USD 0.02 in both periods.

Nine-Month Results

For the nine months ended September 30, 2026, selling, general and administrative expenses were USD 3,662 thousand, against USD 3,188 thousand, and research and development expenses were USD 3,675 thousand, against USD 3,436 thousand. The operating loss was USD 7,173 thousand, against USD 6,217 thousand.

The nine-month loss per share was USD 0.07, compared with USD 0.05 in the same period of 2025. The company reported revenue recognition practices for its Life Sciences segment, noting that revenue from its wellness and lifestyle Business is recognized once goods have been sold to the customer and the performance obligation has been completed.

Liquidity and Going Concern

As of September 30, 2026, the company had cash and cash equivalents of approximately USD 377 thousand and a Working Capital Deficit of approximately USD 1.8 million. The filing describes the company's assessment of its ability to continue as a Going Concern under ASC Subtopic 205-40, which requires evaluating whether conditions or events raise substantial doubt.

The filing also reports that revenue from white-label services is recognized when the performance obligation has been completed and output material has been transferred to the customer.

As of September 30, 2026, the company recognized approximately USD 2.7 million of intangible Assets representing preferential Supply rights and other contractual benefits as a favorable contract received in connection with the sale of assets associated with its Vancouver facility.

The filing also notes that in December 2025 the FASB issued ASU 2025-10 on accounting for government grants, which is effective for annual periods beginning after December 15, 2028, with early adoption permitted.

IGC Pharma Q3 2026 Earnings: Key Takeaways

IGC Pharma reported third quarter 2026 revenue of USD 328 thousand and a loss per share of USD 0.02. Gross margin was 19%, the operating loss was USD 1,931 thousand, and cash and cash equivalents were approximately USD 377 thousand.